Patents by Inventor Randall L. Carpenter

Randall L. Carpenter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating autism
    Patent number: 9044443
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. The humans can be administered the GABA(B) agonist in a single dose or multiple doses.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: June 2, 2015
    Assignee: CLINICAL RESEARCH ASSOCIATES, LLC
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of Treating Autism
    Publication number: 20130261186
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. The humans can be administered the GABA(B) agonist in a single dose or multiple doses.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 3, 2013
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of Treating Fragile X Syndrome
    Publication number: 20130012586
    Abstract: Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of Treating Autism
    Publication number: 20130012587
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of treating autism
    Patent number: 8278276
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: October 2, 2012
    Assignee: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of treating fragile X syndrome
    Patent number: 8273715
    Abstract: Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: September 25, 2012
    Assignee: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • METHODS OF TREATING AUTISM
    Publication number: 20120129940
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.
    Type: Application
    Filed: January 31, 2012
    Publication date: May 24, 2012
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of Treating Fragile X Syndrome
    Publication number: 20120122986
    Abstract: Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.
    Type: Application
    Filed: January 31, 2012
    Publication date: May 17, 2012
    Applicant: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods of treating fragile X syndrome and autism
    Patent number: 8143311
    Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. Subjects having fragile X syndrome are treated with M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: March 27, 2012
    Assignee: Seaside Therapeutics, Inc.
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods for the treatment or inhibition of ileus
    Patent number: 7696220
    Abstract: Methods for the treatment of ileus are disclosed wherein the peripheral mu opioid antagonist methylnaltrexone is administered.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: April 13, 2010
    Assignee: Adolor Corporation
    Inventors: John J. Farrar, Peter J. Schied, William K. Schmidt, Randall L. Carpenter
  • Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism
    Publication number: 20100029770
    Abstract: Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes gamma-aminobutyric acid agonists and/or M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans.
    Type: Application
    Filed: May 14, 2009
    Publication date: February 4, 2010
    Applicant: SeaSide Therapeutics, LLC
    Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
  • Methods for treating cognitive impairment in humans with Multiple Sclerosis
    Patent number: 7619005
    Abstract: Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: November 17, 2009
    Assignee: Cognition Pharmaceuticals LLC
    Inventors: Mel H. Epstein, Kjesten A. Wiig, Randall L. Carpenter
  • Novel methods for the treatment and prevention of ileus
    Publication number: 20020188005
    Abstract: Novel methods for the treatment and/or prevention of ileus. The methods may comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates, quaternary morphinans, opium alkaloid derivatives and quaternary benzomorphans. The methods are particularly suitable for treating and/or preventing postsurgical ileus and postpartum ileus.
    Type: Application
    Filed: June 13, 2002
    Publication date: December 12, 2002
    Applicant: Adolor Corporation
    Inventors: John J. Farrar, Peter J. Schied, William K. Schmidt, Randall L. Carpenter
  • Methods for the treatment and prevention of ileus
    Patent number: 6469030
    Abstract: Methods for the treatment and/or prevention of ileus are disclosed. The methods comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: October 22, 2002
    Assignee: Adolor Corporation
    Inventors: John J. Farrar, Peter J. Schied, William K. Schmidt, Randall L. Carpenter
  • Novel methods for the treatment and prevention of ileus
    Publication number: 20010036951
    Abstract: Novel methods for the treatment and/or prevention of ileus. The methods may comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates, quaternary morphinans, opium alkaloid derivatives and quaternary benzomorphans. The methods are particularly suitable for treating and/or preventing postsurgical ileus and postpartum ileus.
    Type: Application
    Filed: November 29, 2000
    Publication date: November 1, 2001
    Inventors: John J. Farrar, Peter J. Schied, William K. Schmidt, Randall L. Carpenter